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sion or exclusion of the papillary muscles. In relative terms, 
the difference was similar in subjects without hypertrophy. 
This underscores a general need for a uniform approach in 
CMR image analysis.
Keywords Hypertrophic cardiomyopathy ·  
Papillary muscles · Cardiac magnetic resonance · CMR
Introduction
Over the past few years, the use of cardiac magnetic res-
onance (CMR) imaging has steadily increased in patients 
with hypertrophic cardiomyopathy (HCM). Although CMR 
is not yet part of the current risk stratification [1], several 
studies have been undertaken to address the impact of CMR 
for future patient management [2, 3]. In recent publications 
it was demonstrated that left ventricular (LV) ejection frac-
tion (EF) and LV mass can be used to identify HCM patients 
at high risk of adverse cardiac events [2, 4–6]. CMR is the 
current gold standard for quantification of these parameters, 
because of its superior accuracy and reproducibility [7].
In daily practice, uniformity in CMR image analysis is 
lacking on how to deal with measurements of the papil-
lary muscles, despite recommendations in the current CMR 
guidelines. The guidelines state that LV volumes and LV 
mass should be quantified according to the same protocol 
as used for the reference ranges [8, 9]. In general, studies on 
normal values of LV parameters used to include the papil-
lary muscles in the LV mass [10–12]. Surprisingly, in most 
general hospitals exclusion of the papillary muscles has 
become the standard [13].
In HCM patients the papillary muscle mass is higher than 
in normal healthy volunteers [14]. Therefore, especially in 
the HCM population, the impact of the papillary muscles on 
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Abstract
Purpose The use of cardiac magnetic resonance (CMR) 
analysis has increased in patients with hypertrophic cardio-
myopathy (HCM). Quantification of left ventricular (LV) 
measures will be affected by the inclusion or exclusion of 
the papillary muscles as part of the LV mass, but the mag-
nitude of effect and potential consequences are unknown.
Methods We performed Cine-CMR in (1) clinical HCM 
patients (n = 55) and (2) subclinical HCM mutation carriers 
without hypertrophy (n = 14). Absolute and relative differ-
ences in LV ejection fraction (EF) and mass were assessed 
between algorithms with and without inclusion of the papil-
lary muscles.
Results Papillary muscle mass in group 1 was 6.6 ± 2.5 g/m2 
and inclusion of the papillary muscles resulted in significant 
relative increases in LVEF of 4.5 ± 1.8 % and in LV mass of 
8.7 ± 2.6 %. For group 2 these figures were 4.0 ± 0.9 g/m2, 
3.8 ± 1.0 % and 9.5 ± 1.8 %, respectively. With a coefficient 
of variation of 4 %, this 9 % difference in LV mass during 
CMR follow-up will be considered a change, while in fact 
the exact same mass may have been assessed according to 
two different algorithms.
Conclusions In clinical HCM patients, CMR quantification 
of important LV measures is significantly affected by inclu-
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Anderson-Fabry etc.) or any contraindication to CMR imag-
ing were not eligible.
Participants in the present study were either patients with 
an echocardiographically proven HCM according to the 
ACC/ESC guidelines [16] or subjects with an HCM-related 
pathogenic mutation without hypertrophy on echocar-
diography. The former will be referred to as clinical HCM 
patients (group 1, with overt hypertrophy), the latter will be 
referred to as subclinical HCM mutation carriers (group 2, 
without hypertrophy).
CMR image analysis: handling of papillary muscles
The endocardial and epicardial contours were manually 
drawn by one observer in the short-axis images in the LV 
end-diastolic and end-systolic phase using QMass® ver-
sion 7.0 (Medis, Leiden, the Netherlands) (Fig. 1a). The 
end-diastolic phase corresponded to the first image in the 
cine sequence after ECG triggering. The end-systolic phase 
was chosen based on the smallest LV cavity at the mid-ven-
tricular level. At the base of the heart, slices were included 
quantification of LV parameters might be substantial. We 
studied the impact of inclusion and exclusion of the papil-
lary muscles on the quantification of LVEF and LV mass in 
clinical HCM patients with overt hypertrophy. In addition, 
we studied the impact in a group of subclinical HCM muta-
tion carriers without hypertrophy.
Materials and methods
Study population
Study participants were recruited from a population that vis-
ited a specialised HCM outpatient clinic, which routinely 
performs repeated echocardiographic imaging, clinical fol-
low-up and genetic testing according to a cascade strategy. 
Between April 2008 and May 2011 we systematically asked 
them to participate in a study program, which also included 
CMR analysis [15]. Patients with a history of septal reduc-
tion therapy, with LV hypertrophy due to other disorders that 
explain the myocardial hypertrophy (amyloidosis, MELAS, 
Fig. 1 Different methods of assessment of left ventricular (LV) pa-
rameters regarding the papillary muscles and trabecularisations. 
Various image analysis protocols regarding the papillary muscles 
(PMs) and trabecularisations exist. In this study method A and B were 
compared. a LV mass and volume assessed with inclusion of the PMs 
in the LV blood pool. b LV mass and volume assessed with inclusion 
of the PMs in the LV mass. At the base of the PMs the circular shape 
of the endocardial contour was maintained to avoid inclusion of PM 
mass in the endocardial contour. c LV mass and volume assessed with 
inclusion of the PMs and the trabecularisations in the LV mass. Only 
those slices comprising papillary muscle are displayed
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PM mass was obtained according to the following formula:
Statistical analysis
LVEF, mass and PM mass were indexed to body surface 
area and expressed as mean ± SD. Within-group differences 
were compared using a paired samples t-test.
Between group differences were compared using an inde-
pendent samples t-test. A p-value of < 0.05 was considered 
significant. Statistical analysis was performed with IBM 
SPSS Statistics 20.0 (IBM Corp, Armonk, NY, USA).
Results
Study population
Of the 125 attendees of the outpatient clinic, 71 underwent 
CMR and in 2 data were inadequate for further analysis 
(Fig. 2). Finally, we analysed 69 subjects: 55 clinical HCM 
patients (with overt hypertrophy) and 14 subclinical HCM 
mutation carriers (without hypertrophy). Baseline charac-
teristics are displayed in Table 1. Fifty-three clinical HCM 
patients (96 %) were asymptomatic to mildly symptomatic 
(NYHA 1–2) and most pathogenic mutations were located 
in the MYBPC3 gene (70 %).
Impact of the papillary muscles on LV parameters
The results for LVEF and LV mass are displayed per 
group in Table 2. For clinical HCM patients PM mass 
was 6.6 ± 2.5 g/m2. Inclusion or exclusion of the PMs 
resulted in relative differences of 4.5 ± 1.8 % for LVEF and 
8.7 ± 2.6 % for LV mass (p < .01).
if more than 180° of the LV cavity was surrounded by LV 
myocardium [17].
Secondly, the PMs were defined on the short- and long-axis 
images as structures attached to the LV free wall and contigu-
ous with the mitral valve via the chordae tendinae [14]. The 
contours of the PMs were manually drawn on the short-axis 
cine images for each slice that contained PM. A separate con-
tour was used for the anterolateral and posteromedial PM. In 
case of accessory PMs, a continuous contour was used with 
two lines across the blood overlapping each other to avoid 
inclusion of LV blood pool as PM mass (Fig. 1b).
CMR imaging was performed using a 1.5 T MR scan-
ner (Achieva, Philips Healthcare, Eindhoven, the Nether-
lands) with a cardiac coil. Cine images were acquired using 
a breath-hold ECG-triggered segmented SSFP sequence in 
3 long-axis views (2-, 3-, and 4-chamber view) and in mul-
tiple short-axis views with a slice thickness of 10 mm (no 
gap), covering the LV from base to apex.
LV parameters
The LVEF and LV mass were calculated as previously 
described [13, 18, 19]. These calculations were performed 
with results assessed according to two different protocols: 
(1) with inclusion of the PMs in the LV mass and (2) with 
exclusion of the PMs from the LV mass (Fig. 1a and b).
Absolute differences between results according to both 
protocols were calculated by subtraction. The absolute dif-
ferences were transformed to relative differences for each 
LV parameter according to the following formula:
Fig. 2 Flowchart of study 
population. 1. Reasons for non-
participation: 15 not willing to 
participate; 10 Morrow myec-
tomy/Percutaneous transluminal 
septal myocardial ablation; 7 ICD 
or pacemaker; 5 could not be con-
tacted; 5 claustrophobia; 12 other. 
2. Reasons for inadequate CMR 
imaging data: 1 claustrophobia; 
1 inadequate CMR image quality
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the disease process of HCM, the relative differences were 
in the same order of magnitude in the control subjects with-
out hypertrophic myocardium. This underscores the general 
need for uniform protocols, given the potential impact for 
clinical decision-making based upon values of LV mass, 
volume and function.
In recent studies on different CMR image analysis pro-
tocols, the PM mass was combined with that of the tra-
becularisations (Fig. 1c). Inclusion or exclusion of both the 
PMs and the trabecularisations as part of the LV mass led to 
significant differences in LVEF and LV mass [20–22]. This 
was confirmed in HCM patients [13, 23]. Reports on normal 
values with CMR imaging are limited and refer to studies 
that considered the PMs and trabecularisations to be part 
of the LV mass [10–12]. In daily practice, however, these 
structures are often not included, resulting in underestima-
tion of LVEF and LV mass. Normal values for this more 
practical approach of CMR image analysis are scarce. Our 
study points out the need for either uniform CMR image 
analysis including these structures, or the need for studies 
on normal values of the more practical approach.
This is illustrated when our results are put in the con-
text of the excellent reproducibility of CMR image analy-
sis, with a coefficient of variation of 4 % [13, 17, 20, 24]. 
Based on the coefficient of variation we can make statistical 
inferences about the expected results when a particular LV 
mass is measured repeatedly, provided the same methodol-
ogy of CMR image analysis is followed. Appreciating the 
4 % coefficient of variation, the relative differences of the 
repeated measurements of that particular LV mass will lie 
between − 8 % and + 8 % in 95 % of cases. In a setting of 
uniform CMR analysis, this means that a true change in LV 
mass will be present if the results differ by more than a rela-
tive 8 %.
Our finding that the two different approaches of CMR 
analysis result in a 9 % relative difference in LV mass 
should be interpreted in this context. Given the mean rela-
tive difference of 9 %, the exact same LV mass will seem to 
have changed in at least half of the cases. This indicates that 
non-standardised assessment of LV mass may have impor-
tant implications for both research and daily clinical prac-
tice. As for LVEF, the relative difference of 4 % seems less 
important.
In the setting of clinical trials, for example, there is a 
growing interest in studies reporting LV mass and the extent 
of fibrosis relative to LV mass [25, 26]. In case of CMR fol-
low-up studies on this subject, CMR image analysis should 
be performed according to the same protocol at baseline and 
follow-up. Otherwise, differences in LV mass can be inter-
preted as a true change, while in fact it could be the result 
of two CMRs analysed according to two different protocols.
As for daily clinical practice, the use of CMR in HCM 
patients has increased over the years, even though it is not 
For subclinical HCM mutation carriers the PM mass was 
4.0 ± 0.9 g/m2. The relative differences in LVEF and LV 
mass were 3.8 ± 1.0 % and 9.5 ± 1.8 % (p < .01) respectively, 
and not different from the relative figures observed in clini-
cal HCM patients.
The observed absolute differences in LV mass differed 
significantly between groups 1 and 2 (p < .01), while the 
absolute differences in LVEF were not significant (p = 0.13).
Discussion
To our knowledge this is the first study that addresses the 
basic question of how much inclusion or exclusion of the 
PMs affects everyday CMR image analysis in patients with 
HCM in particular, but also in relation to a group of controls 
without hypertrophy. In HCM patients, inclusion of the PMs 
resulted in significant relative increases of 9 % in LV mass 
and 4 % in LVEF. Despite the involvement of the PMs in 
Table 1 Baseline characteristics
Total (n = 69) Clinical HCM 
(n = 55)
Subclinical 
HCM mutation 
carriers (n = 14)
Age (years) 51 ± 16 54 ± 16 40 ± 10
Male 38 (55) 34 (62) 4 (29)
Pathogenic mutation 
present
37 (54) 23 (42) 14 (100)
NYHA class I/II 67 (97) 53 (96) 14 (100)
NYHA class III 2 (3) 2 (4) –
Data are presented as mean ± standard deviation or numbers 
(percentages). HCM hypertrophic cardiomyopathy, NYHA New York 
Heart Association.
Table 2 Impact of inclusion or exclusion of the papillary muscles on 
LV ejection fraction and mass
Clinical HCM (n = 55)
Exclusion 
of PMs 
from LV 
mass
Inclusion 
of PMs in 
LV mass
Absolute 
difference
Relative 
differencea
LVEF (%) 58.2 ± 7.2 60.8 ± 7.6 2.6 ± 1.1 4.5 ± 1.8
LV mass 
(g/m2)
78.5 ± 28.4 85.2 ± 30.3 6.6 ± 2.5 8.7 ± 2.6
Subclinical HCM mutation carriers (n = 14)
Exclusion 
of PMs 
from LV 
mass
Inclusion 
of PMs in 
LV mass
Absolute 
difference
Relative 
differencea
LVEF (%) 57.8 ± 6.1 60.0 ± 6.5 2.2 ± 0.7 3.8 ± 1.0
LV mass 
(g/m2)
42.7 ± 9.9 46.7 ± 10.5 4.0 ± 0.9 9.5 ± 1.8
Data are presented as mean ± standard deviation. Within group 
differences: p < .01. LV left ventricle, EF ejection fraction, PMs 
papillary muscles, HCM hypertrophic cardiomyopathy.
aRelative differences in LVEF and mass are both indicated in 
percentages.
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is supported by a study in healthy controls, which reported a 
similar impact of the PMs on LV mass [31].
It should be appreciated that this study did not address 
accuracy, due to lack of a comparative standard. We merely 
described the impact of a more practical CMR algorithm in 
terms of quantification of LV parameters, and with regard 
to potential consequences for research questions and daily 
clinical practice. In order to put our findings into context, 
we referred to the well-accepted 4 % coefficient of varia-
tion, i.e. a relative difference of 8 % or more indicates a true 
change [13, 17, 20, 24]. In a random set of 20 of our par-
ticipants, intraobserver and interobserver variability were 
4.69 and 4.49 % for LVEF and 4.76 and 4.86 % for LV mass, 
respectively.
In summary, our findings indicate that non-uniform 
CMR image analysis will render incorrect conclusions with 
regard to the presence or absence of changes in important 
LV parameters in about half of patients with two CMR 
assessments. This holds true not only for HCM patients with 
overt hypertrophy but also for subjects without hypertrophy. 
Given the potential impact for both research and daily clini-
cal practice, our data underscore the importance of a stan-
dardised approach, either with or without the PMs as part of 
the LV mass.
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